Hoechst Strong In South Africa: EPS Forecast Up

10 September 1995

The first interim report of Hoechst SA since its successful listing on the South African stock exchange (Marketletter May 22) on July 12 1995, shows a 67% increase in total operating profits to 51.2 million rand ($14 million) for the six months to June 1995.

The group was well positioned to benefit from improved trading conditions, which prevailed during the period under review in virtually all of its operations, resulting in this increase. Based on this performance, the earnings per share forecast for 1995 has been revised to 41.3 cents, up from 37.7 cents in actual EPS last year.

For comparative purposes, the prospectus stated 1994 pro forma EPS of 32.8 cents. In accordance with Johannesburg Stock Exchange requirements, this figure had been adjusted for discontinued operations during the statutory five-year period. Based on this pro forma EPS of 32.8 cents, the increase would have been 25.9%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight